Literature DB >> 21306340

Subtle perturbations of genital microflora alter mucosal immunity among low-risk pregnant women.

Brenna L Anderson1, Susan Cu-Uvin, Christina A Raker, Christine Fitzsimmons, Sharon L Hillier.   

Abstract

OBJECTIVE: Alteration in the vaginal flora has been associated with adverse pregnancy outcomes. The objective of this study was to examine the impact of changes in individual microflora on genital immunity among low-risk pregnant women in early pregnancy.
DESIGN: Cross-sectional study.
SETTING: Large, tertiary care, academic hospital clinic. POPULATION: Low-risk women were enrolled prior to 14 weeks' gestation.
METHODS: Women were included if they had no medical or previous obstetrical complications, were non-smokers, had no sexually transmitted infections and no intercourse in the last 48 hours. Consenting women underwent speculum examination for collection of vaginal culture and Dacron swabs for cytokine analysis. Semi-quantitative vaginal cultures were performed in a reference laboratory. MAIN OUTCOME MEASURES: Concentrations of immune mediators were compared in the presence of various organisms. Concentrations were converted to multiples of the median to standardize the values of each mediator. Regression analyses were performed to control for race.
RESULTS: We enrolled 47 women. The frequencies of genital microorganisms were: H(2)O(2) -producing lactobacilli (70%), Ureaplasma urealyticum (66%), Gardnerella vaginalis (45%), anaerobic non-pigmented Gram-negative rods (ANPGNR, 40%), anaerobic pigmented Gram-negative rods (APGNR, 17%). After adjusting for race and body mass index, interleukin-1β, interferon-γ, tumor necrosis factor-α and granulocyte macrophage-colony stimulating factor were increased in the presence of G. vaginalis, ANPGNR, and APGNR. There was no consistent impact on the other markers of immune activation.
CONCLUSION: The presence of individual species impacts genital immunity among low-risk pregnant women. Perturbations in genital immunity could partially explain heterogeneity in adverse pregnancy outcomes.
© 2011 The Authors Acta Obstetricia et Gynecologica Scandinavica© 2011 Nordic Federation of Societies of Obstetrics and Gynecology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21306340      PMCID: PMC5860914          DOI: 10.1111/j.1600-0412.2011.01082.x

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  29 in total

1.  Decreased cervical proinflammatory cytokines permit subsequent upper genital tract infection during pregnancy.

Authors:  Hyagriv N Simhan; Steve N Caritis; Marijane A Krohn; Begoña Martinez de Tejada; Daniel V Landers; Sharon L Hillier
Journal:  Am J Obstet Gynecol       Date:  2003-08       Impact factor: 8.661

2.  Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: aerobic vaginitis.

Authors:  Gilbert G G Donders; Annie Vereecken; Eugene Bosmans; Alfons Dekeersmaecker; Geert Salembier; Bernard Spitz
Journal:  BJOG       Date:  2002-01       Impact factor: 6.531

3.  TNF, IL-1, IL-6, IL-8 and soluble TNF receptors in relation to chorioamnionitis and premature labor.

Authors:  K J Arntzen; A M Kjøllesdal; J Halgunset; L Vatten; R Austgulen
Journal:  J Perinat Med       Date:  1998       Impact factor: 1.901

4.  Impact of metronidazole therapy on preterm birth in women with bacterial vaginosis flora (Gardnerella vaginalis): a randomised, placebo controlled trial.

Authors:  H M McDonald; J A O'Loughlin; R Vigneswaran; P T Jolley; J A Harvey; A Bof; P J McDonald
Journal:  Br J Obstet Gynaecol       Date:  1997-12

5.  Intravaginal clindamycin treatment for bacterial vaginosis: effects on preterm delivery and low birth weight.

Authors:  M R Joesoef; S L Hillier; G Wiknjosastro; H Sumampouw; M Linnan; W Norojono; A Idajadi; B Utomo
Journal:  Am J Obstet Gynecol       Date:  1995-11       Impact factor: 8.661

6.  Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations.

Authors:  R Amsel; P A Totten; C A Spiegel; K C Chen; D Eschenbach; K K Holmes
Journal:  Am J Med       Date:  1983-01       Impact factor: 4.965

7.  IL-1beta, IL-6, TNFalpha, fetal fibronectin, and endotoxin in the lower genital tract of pregnant women with bacterial vaginosis.

Authors:  I Mattsby-Baltzer; J J Platz-Christensen; N Hosseini; P Rosén
Journal:  Acta Obstet Gynecol Scand       Date:  1998-08       Impact factor: 3.636

8.  Antibiotic treatment of bacterial vaginosis in pregnancy: a meta-analysis.

Authors:  Harald Leitich; Mathias Brunbauer; Barbara Bodner-Adler; Alexandra Kaider; Christian Egarter; Peter Husslein
Journal:  Am J Obstet Gynecol       Date:  2003-03       Impact factor: 8.661

9.  Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group.

Authors:  S L Hillier; R P Nugent; D A Eschenbach; M A Krohn; R S Gibbs; D H Martin; M F Cotch; R Edelman; J G Pastorek; A V Rao
Journal:  N Engl J Med       Date:  1995-12-28       Impact factor: 91.245

Review 10.  Antibiotics for treating bacterial vaginosis in pregnancy.

Authors:  H McDonald; P Brocklehurst; J Parsons; R Vigneswaran
Journal:  Cochrane Database Syst Rev       Date:  2003
View more
  11 in total

Review 1.  Does the vaginal microbiota play a role in the development of cervical cancer?

Authors:  Maria Kyrgiou; Anita Mitra; Anna-Barbara Moscicki
Journal:  Transl Res       Date:  2016-07-15       Impact factor: 7.012

2.  Interaction between lactobacilli, bacterial vaginosis-associated bacteria, and HIV Type 1 RNA and DNA Genital shedding in U.S. and Kenyan women.

Authors:  Caroline Mitchell; Jennifer E Balkus; David Fredricks; Congzhou Liu; Jennifer McKernan-Mullin; Lisa M Frenkel; Christina Mwachari; Amneris Luque; Susan E Cohn; Craig R Cohen; Robert Coombs; Jane Hitti
Journal:  AIDS Res Hum Retroviruses       Date:  2012-11-05       Impact factor: 2.205

Review 3.  The Human Microbiome during Bacterial Vaginosis.

Authors:  Andrew B Onderdonk; Mary L Delaney; Raina N Fichorova
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

Review 4.  The influence of the commensal microbiota on distal tumor-promoting inflammation.

Authors:  Claire M Buchta Rosean; Melanie R Rutkowski
Journal:  Semin Immunol       Date:  2017-07-04       Impact factor: 11.130

5.  Pregnancy-induced changes in immune protection of the genital tract: defining normal.

Authors:  Brenna L Anderson; Hector Mendez-Figueroa; Joshua D Dahlke; Christina Raker; Sharon L Hillier; Susan Cu-Uvin
Journal:  Am J Obstet Gynecol       Date:  2013-01-10       Impact factor: 8.661

6.  Hydrogen Peroxide-Producing Lactobacilli Are Associated With Lower Levels of Vaginal Interleukin-1β, Independent of Bacterial Vaginosis.

Authors:  Caroline Mitchell; David Fredricks; Kathy Agnew; Jane Hitti
Journal:  Sex Transm Dis       Date:  2015-07       Impact factor: 2.830

Review 7.  The vaginal microbiota, human papillomavirus infection and cervical intraepithelial neoplasia: what do we know and where are we going next?

Authors:  Anita Mitra; David A MacIntyre; Julian R Marchesi; Yun S Lee; Phillip R Bennett; Maria Kyrgiou
Journal:  Microbiome       Date:  2016-11-01       Impact factor: 14.650

8.  Determinants of the Nasal Microbiome: Pilot Study of Effects of Intranasal Medication Use.

Authors:  Vijay R Ramakrishnan; Justin Holt; Leah F Nelson; Diana Ir; Charles E Robertson; Daniel N Frank
Journal:  Allergy Rhinol (Providence)       Date:  2018-08-02

9.  Cervical microbiota in women with cervical intra-epithelial neoplasia, prior to and after local excisional treatment, a Norwegian cohort study.

Authors:  Johanna Wiik; Verena Sengpiel; Maria Kyrgiou; Staffan Nilsson; Anita Mitra; Tom Tanbo; Christine Monceyron Jonassen; Tone Møller Tannæs; Katrine Sjøborg
Journal:  BMC Womens Health       Date:  2019-02-06       Impact factor: 2.809

10.  The vaginal microbiota associates with the regression of untreated cervical intraepithelial neoplasia 2 lesions.

Authors:  Anita Mitra; David A MacIntyre; George Ntritsos; Ann Smith; Konstantinos K Tsilidis; Julian R Marchesi; Phillip R Bennett; Anna-Barbara Moscicki; Maria Kyrgiou
Journal:  Nat Commun       Date:  2020-04-24       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.